JPWO2020232156A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020232156A5 JPWO2020232156A5 JP2021568229A JP2021568229A JPWO2020232156A5 JP WO2020232156 A5 JPWO2020232156 A5 JP WO2020232156A5 JP 2021568229 A JP2021568229 A JP 2021568229A JP 2021568229 A JP2021568229 A JP 2021568229A JP WO2020232156 A5 JPWO2020232156 A5 JP WO2020232156A5
- Authority
- JP
- Japan
- Prior art keywords
- solvate
- pharmaceutically acceptable
- acceptable salt
- compound
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims 16
- 239000012453 solvate Substances 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 13
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 7
- 229910052805 deuterium Inorganic materials 0.000 claims 7
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 4
- QOHACAHSZDTBQL-WQNTXASMSA-N BrC=1C=C(C=C(C=1O)Br)C(=O)C1=C(OC2=C1C(=C(C(=C2[2H])O)[2H])[2H])C(C)O Chemical compound BrC=1C=C(C=C(C=1O)Br)C(=O)C1=C(OC2=C1C(=C(C(=C2[2H])O)[2H])[2H])C(C)O QOHACAHSZDTBQL-WQNTXASMSA-N 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 201000005569 Gout Diseases 0.000 claims 1
- 201000001431 Hyperuricemia Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000005414 inactive ingredient Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962847519P | 2019-05-14 | 2019-05-14 | |
| US62/847,519 | 2019-05-14 | ||
| PCT/US2020/032725 WO2020232156A1 (en) | 2019-05-14 | 2020-05-13 | Compound for treating gout or hyperuricemia |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022533958A JP2022533958A (ja) | 2022-07-27 |
| JP2022533958A5 JP2022533958A5 (https=) | 2023-05-15 |
| JPWO2020232156A5 true JPWO2020232156A5 (https=) | 2023-05-15 |
| JP7656548B2 JP7656548B2 (ja) | 2025-04-03 |
Family
ID=73288915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021568229A Active JP7656548B2 (ja) | 2019-05-14 | 2020-05-13 | 痛風または高尿酸血症を処置するための化合物 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220242841A1 (https=) |
| EP (1) | EP3968989A4 (https=) |
| JP (1) | JP7656548B2 (https=) |
| KR (1) | KR20220016105A (https=) |
| CN (1) | CN113874014A (https=) |
| AU (2) | AU2020274165A1 (https=) |
| BR (1) | BR112021022843A2 (https=) |
| CA (1) | CA3140412A1 (https=) |
| IL (1) | IL288034B1 (https=) |
| MA (1) | MA55973A (https=) |
| MX (1) | MX2021013980A (https=) |
| SG (1) | SG11202112562XA (https=) |
| TW (1) | TW202108561A (https=) |
| WO (1) | WO2020232156A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202105743RA (en) | 2018-12-06 | 2021-06-29 | Arthrosi Therapeutics Inc | Methods for treating or preventing gout or hyperuricemia |
| KR102946486B1 (ko) | 2018-12-06 | 2026-03-31 | 아쓰로시 테라퓨틱스, 인크. | 통풍 또는 고뇨산혈증의 치료 또는 예방을 위한 화합물의 결정형 |
| KR20230024354A (ko) * | 2020-06-10 | 2023-02-20 | 아쓰로시 테라퓨틱스, 인크. | 만성 신장 질환을 치료 또는 예방하는 방법 |
| WO2023058975A1 (ko) * | 2021-10-07 | 2023-04-13 | (주)이노보테라퓨틱스 | 벤조퓨라닐 히드록시페닐 메타논 유도체를 포함하는 hsp47 억제용 약학 조성물 |
| TW202330485A (zh) * | 2021-12-02 | 2023-08-01 | 美商安索治療公司 | 用於治療或預防痛風或高尿酸血症之化合物的結晶形式 |
| WO2023125667A1 (en) * | 2021-12-30 | 2023-07-06 | Arthrosi Therapeutics, Inc. | Preparation of a compound for the treatment of gout or hyperuricemia |
| US20250242050A1 (en) | 2024-01-31 | 2025-07-31 | The Industry & Academic Cooperation In Chungnam National University (Iac) | Composition for treating gout containing cyclodextrin-conjugated polymer nano-drug and method for treating gout |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9962362B2 (en) * | 2012-03-29 | 2018-05-08 | Children's Hospital Medical Center | Use of small molecule inhibitors targeting EYA tyrosine phosphatase |
| EP3484862B1 (en) * | 2016-07-18 | 2021-09-01 | Arthrosi Therapeutics, Inc. | Compounds, compositions and methods for treating or preventing a symptom associated with gout or hyperuricemia |
| US20210130312A1 (en) * | 2018-04-03 | 2021-05-06 | Children's Hospital Medical Center | Inhibitors of eya3-protein tyrosine phosphatase in dna damage repair signaling of pulmonary arterial hypertension |
| KR102946486B1 (ko) * | 2018-12-06 | 2026-03-31 | 아쓰로시 테라퓨틱스, 인크. | 통풍 또는 고뇨산혈증의 치료 또는 예방을 위한 화합물의 결정형 |
-
2020
- 2020-05-13 WO PCT/US2020/032725 patent/WO2020232156A1/en not_active Ceased
- 2020-05-13 KR KR1020217041035A patent/KR20220016105A/ko active Pending
- 2020-05-13 IL IL288034A patent/IL288034B1/en unknown
- 2020-05-13 TW TW109115899A patent/TW202108561A/zh unknown
- 2020-05-13 JP JP2021568229A patent/JP7656548B2/ja active Active
- 2020-05-13 EP EP20804806.6A patent/EP3968989A4/en active Pending
- 2020-05-13 MA MA055973A patent/MA55973A/fr unknown
- 2020-05-13 US US17/610,673 patent/US20220242841A1/en active Pending
- 2020-05-13 SG SG11202112562XA patent/SG11202112562XA/en unknown
- 2020-05-13 AU AU2020274165A patent/AU2020274165A1/en not_active Abandoned
- 2020-05-13 CA CA3140412A patent/CA3140412A1/en active Pending
- 2020-05-13 CN CN202080035809.1A patent/CN113874014A/zh active Pending
- 2020-05-13 MX MX2021013980A patent/MX2021013980A/es unknown
- 2020-05-13 BR BR112021022843A patent/BR112021022843A2/pt unknown
-
2026
- 2026-03-23 AU AU2026202224A patent/AU2026202224A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111989332A (zh) | 作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用 | |
| JP2020169171A5 (https=) | ||
| JP2006509749A5 (https=) | ||
| JP2020023528A5 (https=) | ||
| JP2020500862A5 (https=) | ||
| RU2015154955A (ru) | Производные бензотиофенов в качестве ингибиторов рецептора эстрогенов | |
| JP2023106403A5 (https=) | ||
| JP2010530372A5 (https=) | ||
| JP2004517049A5 (https=) | ||
| JP2009536660A5 (https=) | ||
| JPWO2020131674A5 (https=) | ||
| RU2011133128A (ru) | Противоопухолевые соединения дигидропиран-2-она | |
| JP2005508337A5 (https=) | ||
| JP2022137237A5 (https=) | ||
| JP2017522304A5 (https=) | ||
| JP2010503620A5 (https=) | ||
| JP2011509302A5 (https=) | ||
| JP2007503432A5 (https=) | ||
| JPWO2020232156A5 (https=) | ||
| JP2004531478A5 (https=) | ||
| JP2024112835A5 (https=) | ||
| JPWO2022221227A5 (https=) | ||
| CN114209701A (zh) | 沃替西汀及其衍生物的抗肿瘤活性和应用 | |
| JP2003508523A5 (https=) | ||
| CN103183640A (zh) | 二芳基吡唑类化合物及其制备方法与用途 |